A new top three at Xenios AG

Changes in the Management Board for the extracorporeal heart&lung therapy specialist

ID: 1566143
recent pressrelease next pressrelease

(PresseBox) - The Management Board of Xenios AG, the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective January 31, 2021, the previous Chair of the Executive Board, Dr. Andreas Terpin, has left the company. The new senior trio on the Management Board will continue Fresenius Medical Care?s success in the field of extracorporeal heart & lung therapies.

The Management Board contract with Dr. Andreas Terpin ended on January 31, 2021. After three successful years at Xenios AG, Dr. Terpin is pursuing new projects at Fresenius Medical Care.

As part of this, Mr. J

Responsibilities are divided up as follows on the Management Board: Mr. Jthe success of Fresenius Medical Care and Xenios AG in the field of extracorporeal heart & lung therapies.

On behalf of the company, the Supervisory Board of Xenios AG would like to thank Dr. Terpin most sincerely for his significant contribution to the successful development of Xenios AG in recent years. He leaves behind a well-established and stable company, especially after a very challenging yet successful year in 2020.

Xenios AG - a company of the Fresenius Medical Care Group - is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console.

Xenios mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients that are more awake, more self-determined and more mobile.

Xenios AG has been part of Fresenius Medical Care, the world''s leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group''s portfolio in the area of holistic multi-organ support of FME.

www.xenios-ag.com



More information:
http://https://www.kawebook.com https://



Keywords (optional):



Company information / Profile:

Xenios AG - a company of the Fresenius Medical Care Group - is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console.Xenios mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients that are more awake, more self-determined and more mobile.Xenios AG has been part of Fresenius Medical Care, the world''s leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group''s portfolio in the area of holistic multi-organ support of FME.www.xenios-ag.com

PressRelease by

Requests:



PressContact / Agency:



published by: PresseBox
print pressrelease  send to a friend  

Date: 03/31/2021 - 03:34
Language: English
News-ID 1566143
Character count: 4577
Kontakt-Informationen:
Firma: Xenios AG
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Heilbronn
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 235

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 441
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 90


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.